<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25248" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Monoclonal Gammopathy of Undetermined Significance</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kaseb</surname>
            <given-names>Hatem</given-names>
          </name>
          <aff>Cleveland Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Annamaraju</surname>
            <given-names>Pavan</given-names>
          </name>
          <aff>Loma Linda University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Babiker</surname>
            <given-names>Hani M.</given-names>
          </name>
          <aff>University of Arizona Cancer Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hatem Kaseb declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pavan Annamaraju declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hani Babiker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25248.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Monoclonal gammopathy of undetermined significance (MGUS) is an asymptomatic preneoplastic plasma cell disorder that is characterized by serum M-protein less than 30 g/L, bone marrow clonal plasma cells less than 10 percent, absence of plasma cell myeloma-related end-organ damage (hypercalcemia, renal insufficiency, anemia, or bone lesions) and absence of B-cell lymphoma or other diseases known to produce an M-protein. MGUS is generally considered a preneoplastic disorder that does not always progress to overt malignancy. This activity describes the pathophysiology, presentation, evaluation, and treatment of monoclonal gammopathy of undetermined significance and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the pathophysiology of monoclonal gammopathy of undetermined significance.</p></list-item><list-item><p>Describe the presentation of monoclonal gammopathy of undetermined significance.</p></list-item><list-item><p>Review the treatment options for monoclonal gammopathy of undetermined significance.</p></list-item><list-item><p>Outline interprofessional team strategies for enhancing care coordination and communication to advance the evaluation and management of monoclonal gammopathy of undetermined significance and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25248&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25248">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25248.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Monoclonal gammopathy of undetermined&#x000a0;significance (MGUS) is an asymptomatic premalignant plasma cell disorder that is characterized by the presence of serum M-protein less than 30 g/L or 3 g/dL, bone marrow (BM) clonal plasma cells less than 10%, absence of plasma cell myeloma (PCM) related end-organ damage (CRAB symptoms: hypercalcemia, renal insufficiency, anemia and, bone lesions) and absence of B-cell lymphoma or other disease known to produce an M-protein. MGUS is generally considered a preneoplastic disorder that does not always progress to overt malignancy. There are three distinct types of MGUS:<xref ref-type="bibr" rid="article-25248.r1">[1]</xref></p>
        <list list-type="order">
          <list-item>
            <p>Non-IgM MGUS: Non-IgM MGUS (IgG, IgA, IgD) accounts for the majority of MGUS cases and is characterized by a monoclonal plasma cell.</p>
          </list-item>
          <list-item>
            <p>IgM MGUS</p>
          </list-item>
          <list-item>
            <p>Light-chain MGUS</p>
          </list-item>
        </list>
        <p>Non-IgM MGUS may progress to a malignant plasma cell neoplasm. IgM MGUS may develop into Waldenstrom macroglobulinemia, immunoglobulin light chain (AL) amyloidosis, or lymphoma. Light chain MGUS (LC-MGUS) is characterized by a monoclonal protein that lacks the immunoglobulin heavy chain component. LC-MGUS may show progression to idiopathic Bence Jones proteinuria, light chain PCM, AL&#x000a0;amyloidosis, or light chain deposition disease. According to a population-based cohort study, the risk of progression to multiple myeloma in patients with light-chain MGUS is 0.3%.<xref ref-type="bibr" rid="article-25248.r2">[2]</xref><xref ref-type="bibr" rid="article-25248.r3">[3]</xref></p>
      </sec>
      <sec id="article-25248.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>No specific cause of non-IgM MGUS has been identified. However, the disease may be associated with some non-malignant disorders such as connective tissue disorders, peripheral neuropathies, dermatological diseases such as acquired C1 esterase inhibitor deficiency (angioedema), endocrine diseases, and liver infections such as hepatitis C virus infection and HIV liver disease.<xref ref-type="bibr" rid="article-25248.r2">[2]</xref><xref ref-type="bibr" rid="article-25248.r4">[4]</xref><xref ref-type="bibr" rid="article-25248.r5">[5]</xref>&#x000a0;Population-based studies from northern Europe and the United States show increased risk of MGUS among first-degree relatives of those with MGUS or myeloma,&#x000a0;supporting a role for germline susceptibility genes, shared environmental influences, or an interaction between both.<xref ref-type="bibr" rid="article-25248.r6">[6]</xref><xref ref-type="bibr" rid="article-25248.r7">[7]</xref></p>
      </sec>
      <sec id="article-25248.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Monoclonal gammopathy of undetermined&#x000a0;significance (MGUS) is found in approximately 2% to 3% of adults over age 50 and in 5% of adults older than the age of 70. MGUS is more common in men than&#x000a0;in women (1.5:1) and 2 to 3-fold more common in African Americans compared to Caucasians. Non-IgM MGUS represents up to 85% of MGUS cases; IgM MGUS represents up to 15% of MGUS cases.<xref ref-type="bibr" rid="article-25248.r2">[2]</xref><xref ref-type="bibr" rid="article-25248.r4">[4]</xref></p>
      </sec>
      <sec id="article-25248.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The clonal plasma cells producing non-IgM MGUS reside in the bone marrow (BM). These cells harbor somatic hypermutation of the variable regions and are class-switched. The majority of non-IgM MGUS are IgG, followed by IgA, bi-clonal, and IgD.<xref ref-type="bibr" rid="article-25248.r1">[1]</xref><xref ref-type="bibr" rid="article-25248.r5">[5]</xref></p>
      </sec>
      <sec id="article-25248.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The majority of non-IgM MGUS patients are asymptomatic. According to the 2014 International Myeloma Working Group updated criteria, the diagnosis of non-IgM MGUS is based on three criteria:</p>
        <list list-type="order">
          <list-item>
            <p>Serum monoclonal protein less than 30 g/L (3 g/dL)</p>
          </list-item>
          <list-item>
            <p>Less than 10% of clonal plasma cells in the bone marrow</p>
          </list-item>
          <list-item>
            <p>The absence of CRAB symptoms (hypercalcemia, renal insufficiency, anemia and, bone lesions suspicious for PCM)</p>
          </list-item>
        </list>
        <p>Non-IgM MGUS is usually diagnosed as an incidental finding on protein electrophoresis performed as part of an evaluation for disorders or disease presentation of peripheral neuropathy, vasculitis, hemolytic anemia, skin rashes, hypercalcemia, elevated erythrocyte sedimentation rate. Non-IgM MGUS is generally not considered a neoplastic process, with an annual risk of progression of 1%. Non-IgM MGUS may progress to PCM, solitary plasmacytoma, or amyloidosis. Two important factors influence non-IgM MGUS progression. The first is the size and type of M protein, and the second is the level of immunoglobulin (less than 5 g/L and greater than 25 g/L).<xref ref-type="bibr" rid="article-25248.r8">[8]</xref><xref ref-type="bibr" rid="article-25248.r1">[1]</xref><xref ref-type="bibr" rid="article-25248.r5">[5]</xref></p>
      </sec>
      <sec id="article-25248.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Non-IgM MGUS needs a thorough set of investigations to exclude this disease entity from the other plasma cell neoplasms. Investigations should include complete blood count (CBC), bone marrow aspirate/biopsy (BMA/BMB), immunohistochemical analysis (IHC), serum calcium and creatinine, serum protein electrophoresis and immunofixation, urine protein electrophoresis and immunofixation, serum-free light chains (FLC) assay, quantification of immunoglobulins, immunophenotyping utilizing flow cytometry and cross-sectional imaging studies.<xref ref-type="bibr" rid="article-25248.r8">[8]</xref><xref ref-type="bibr" rid="article-25248.r1">[1]</xref></p>
        <p>CBC/peripheral smear is usually normal. However, some cases may show rouleaux formation. BMB usually shows 3% to 5% mature plasma cells (less than 10%) evenly scattered or in occasional small clusters. CD138 is useful in highlighting these plasma cells in the BMB. IHC of the plasma cells for kappa and lambda will demonstrate monoclonal restriction. MGUS is characterized by the presence of a monoclonal (M) protein which is produced by clonal plasma cells and detected by serum and urine protein electrophoresis, and immunofixation of the serum and urine. Immunophenotyping shows monoclonal plasma cells that are CD38+ (bright) cells with an aberrant CD56 population (may also be negative). Molecular testing for non-IgM MGUS has shown that this disease entity usually shows a normal karyotype because of the relatively small number of plasma cells. Some patients show chromosomal alterations of PCM that include: t(11;14), t(4;14), t(14;16), deletions of 13q and hyperdiploid. No clinical correlation for these genetic alterations has been found in non-IgM MGUS.<xref ref-type="bibr" rid="article-25248.r9">[9]</xref><xref ref-type="bibr" rid="article-25248.r1">[1]</xref></p>
        <p>The 2019 International myeloma working group (IMWG), consensus recommends the following approach for cross-sectional imaging in MGUS:<xref ref-type="bibr" rid="article-25248.r10">[10]</xref></p>
        <p>Whole-body imaging is recommended only in high-risk MGUS. Since IgM-MGUS usually progresses to Waldenstrom macroglobulinemia and not multiple myeloma, routine bone imaging is not recommended.</p>
        <p>In suspected high-risk non-IgM MGUS, a whole-body CT to rule out multiple myeloma is recommended. CT scan has superior sensitivity compared with a skeletal survey for the detection of osteolytic lesions in patients with multiple myeloma.</p>
        <p>If whole-body CT is not available, conventional skeletal survey or whole-body MRI are alternatives.</p>
        <p>In patients with equivocal findings on whole-body CT (or conventional skeletal survey) in whom there is a concern for myeloma development, a whole-body MRI is recommended (or MRI of the spine and pelvis if whole-body MRI is not available).</p>
        <p>If whole-body CT is positive, a PET/CT should be done. A follow-up bone imaging is not recommended unless there are signs of progression to symptomatic disease (e.g., pain or increase in serological parameters).</p>
        <p>In patients with MGUS with positive imaging findings for focal and osteolytic lesions, other malignancies should be ruled out as well. If needed, a biopsy of such a lesion should be performed.</p>
      </sec>
      <sec id="article-25248.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment is usually not recommended for patients with MGUS.&#x000a0;As there is a risk of progression to lymphoproliferative malignancy long-term follow-up is advised.</p>
        <p>If a patient has an IgM M-protein, bone marrow&#x000a0;biopsy and computed tomography (CT) scanning of the abdomen may be helpful in detecting Waldenstr&#x000f6;m macroglobulinemia or other lymphoproliferative disorders.</p>
        <p>MGUS-associated neuropathies are usually not treated, except in the case of a disabling IgM monoclonal gammopathy or IgG/IgA MGUS associated with chronic inflammatory demyelinating neuropathy (CIDP). About 80% of patients with IgG/IgA MGUS CIDP respond to one of the typical CIDP treatments and some patients stabilize without therapy.&#x000a0;MGUS patients with associated osteopenia or osteoporosis&#x000a0;may benefit from treatment with intravenous bisphosphonates.</p>
        <p>The intensity of follow-up in patients with MGUS is guided by risk stratification. Initial follow-up at six months is recommended, with subsequent visits scheduled according to the level of risk.&#x000a0;If&#x000a0;clinical trials of preventive strategies are available, patients at high risk for progression should be encouraged to participate.</p>
      </sec>
      <sec id="article-25248.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>It is crucial to distinguish non-IgM MGUS from other advanced plasma cell neoplasms since these diseases will require a different management approach. The differential diagnosis of non-IgM MGUS include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Plasma cell myeloma (smoldering or symptomatic): Any patient with a non-IgM serum monoclonal protein greater than or equal to 30 g/L or with greater than or equal to 10% clonal plasma cells in the bone marrow should not be diagnosed as non-IgM MGUS. Many providers consider smoldering PCM as a transition stage between non-IgM MGUS and symptomatic PCM. Smoldering PCM is distinguished from MGUS based on the size of the M protein and the percentage of clonal plasma cells in the bone marrow. Smoldering PCM is distinguished from symptomatic PCM by the presence of CRAB symptoms.<xref ref-type="bibr" rid="article-25248.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Waldenstr&#x000f6;m macroglobulinemia (smoldering or symptomatic): WM is a distinct clinicopathologic disorder that shows lymphoplasmacytic lymphoma (LPL) in the bone marrow and an IgM monoclonal gammopathy. Symptoms include blood hyperviscosity, lymphadenopathy, or splenomegaly. The WHO (2017) diagnostic criteria of WM include:<xref ref-type="bibr" rid="article-25248.r5">[5]</xref>
<list list-type="order"><list-item><p>IgM monoclonal gammopathy</p></list-item><list-item><p>Clonal plasma cells less than 10%</p></list-item><list-item><p>Absence of end-organ damage (CRAB symptoms)</p></list-item><list-item><p>Absence of symptoms or signs of amyloidosis</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Monoclonal gammopathy of renal significance: This disease entity is diagnosed when the patient has diagnostic criteria for MGUS as well as renal insufficiency and monoclonal immunoglobulin deposits in the kidney by immunofluorescence.<xref ref-type="bibr" rid="article-25248.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Light chain smoldering multiple myeloma (idiopathic Bence Jones proteinuria): The diagnostic criteria of LC-SMM include:
<list list-type="order"><list-item><p>Monoclonal light chains in the urine (Bence Jones proteinuria)</p></list-item><list-item><p>No immunoglobulin heavy chain expression in the serum or urine</p></list-item><list-item><p>No symptoms of PCM, WM, or amyloid light chain amyloidosis</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Primary (amyloid light chain) amyloidosis and light chain deposition disease: This entity of plasma cell neoplasms is associated with the pathologic deposition of monoclonal light chains in tissue. The diagnostic criteria include the presence of amyloid in tissue and evidence of plasma cell neoplasm.</p>
          </list-item>
          <list-item>
            <p>B cell lymphoproliferative disorder</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25248.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Non-IgM MGUS is considered a preneoplastic condition with an annual risk of progression of approximately 1%. The risk&#x000a0;of progression is increased when M protein greater than or equal to 15 g/L and with an abnormal free light chain ratio. Non-IgM MGUS does not require treatment. However, the management of patients with non-IgM MGUS requires an understanding of the risk of progression of the disease. Generally, close follow-up is recommended for these patients. Most providers believe that all non-IgM MGUS patients should undergo a clinical examination and laboratory evaluation for disease progression annually.<xref ref-type="bibr" rid="article-25248.r8">[8]</xref>&#x000a0;The patients with MGUS who are at risk for progressing to advanced disease can be risk-stratified based on the following criteria:</p>
        <list list-type="order">
          <list-item>
            <p>Serum monoclonal protein level greater than or equal to 15 g/L (1.5 g/dL)</p>
          </list-item>
          <list-item>
            <p>Non-IgG MGUS (i.e., IgA, IgM, and IgD MGUS)</p>
          </list-item>
          <list-item>
            <p>Abnormal serum free light chain ratio</p>
          </list-item>
        </list>
        <p>Patients with three risk factors are categorized as high-risk MGUS; patients with two risk factors are categorized as high-intermediate risk MGUS. Patients with one risk factor are categorized as low-intermediate risk MGUS. Patients with no risk factors are categorized as low-risk MGUS. Despite close observation, some non-IgM MGUS patients may show progression to PCM abruptly.<xref ref-type="bibr" rid="article-25248.r9">[9]</xref><xref ref-type="bibr" rid="article-25248.r5">[5]</xref><xref ref-type="bibr" rid="article-25248.r12">[12]</xref><xref ref-type="bibr" rid="article-25248.r13">[13]</xref><xref ref-type="bibr" rid="article-25248.r14">[14]</xref></p>
      </sec>
      <sec id="article-25248.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Monoclonal gammopathy of undetermined&#x000a0;significance (MGUS) can progress&#x000a0;to develop myeloproliferative disorders or other serious conditions such as:</p>
        <list list-type="bullet">
          <list-item>
            <p>Multiple myeloma</p>
          </list-item>
          <list-item>
            <p>Light chain amyloidosis</p>
          </list-item>
          <list-item>
            <p>Waldenstrom macroglobulinemia</p>
          </list-item>
          <list-item>
            <p>Lymphoma</p>
          </list-item>
          <list-item>
            <p>Osteoporosis</p>
          </list-item>
          <list-item>
            <p>Venous thromboembolism</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25248.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Monoclonal gammopathy of undetermined&#x000a0;significance (MGUS) patients have no specific treatment, they should undergo detail clinical examination, serum, and urine protein electrophoresis regularly every six to twelve months to look for disease progression. Patients with osteopenia or osteoporosis may benefit from bisphosphonate therapy.</p>
      </sec>
      <sec id="article-25248.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Monoclonal gammopathy of undetermined&#x000a0;significance (MGUS) is best managed by an interprofessional team that includes primary care providers, hematologists, medical oncologists, and nurses. There is no specific treatment for these patients, they only need long-term follow-up because of the potential to progress to myeloproliferative disorders and numerous other complications.</p>
      </sec>
      <sec id="article-25248.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25248&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25248">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/monoclonal-gammopathy-of-undetermined-significance/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25248">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25248/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25248">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25248.s15">
        <title>References</title>
        <ref id="article-25248.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Dimopoulos</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Palumbo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Blade</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Merlini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mateos</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hillengass</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kastritis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Landgren</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Paiva</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>LeLeu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zweegman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lonial</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosinol</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zamagni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jagannath</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sezer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kristinsson</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Caers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Usmani</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Lahuerta</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Johnsen</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Beksac</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cavo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldschmidt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Terpos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Durie</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Miguel</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.</article-title>
            <source>Lancet Oncol</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>15</volume>
            <issue>12</issue>
            <fpage>e538</fpage>
            <page-range>e538-48</page-range>
            <pub-id pub-id-type="pmid">25439696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal gammopathy of undetermined significance.</article-title>
            <source>Br J Haematol</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>134</volume>
            <issue>6</issue>
            <fpage>573</fpage>
            <page-range>573-89</page-range>
            <pub-id pub-id-type="pmid">16938117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Katzmann</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Melton</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Therneau</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Bradwell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jelinek</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.</article-title>
            <source>Lancet</source>
            <year>2010</year>
            <month>May</month>
            <day>15</day>
            <volume>375</volume>
            <issue>9727</issue>
            <fpage>1721</fpage>
            <page-range>1721-8</page-range>
            <pub-id pub-id-type="pmid">20472173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinhold</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Rawstron</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>F&#x000f6;rsti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Doughty</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vijayakrishnan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Broderick</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dahir</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Begum</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Hosking</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>M&#x000fc;hleisen</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Langer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>D&#x000f6;rner</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>J&#x000f6;ckel</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Eisele</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>N&#x000f6;then</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hose</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Goldschmidt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Hemminki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Houlston</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Inherited genetic susceptibility to monoclonal gammopathy of unknown significance.</article-title>
            <source>Blood</source>
            <year>2014</year>
            <month>Apr</month>
            <day>17</day>
            <volume>123</volume>
            <issue>16</issue>
            <fpage>2513</fpage>
            <page-range>2513-7; quiz 2593</page-range>
            <pub-id pub-id-type="pmid">24449210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swerdlow</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Campo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pileri</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Advani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ghielmini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Salles</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Zelenetz</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>ES</given-names>
              </name>
            </person-group>
            <article-title>The 2016 revision of the World Health Organization classification of lymphoid neoplasms.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>May</month>
            <day>19</day>
            <volume>127</volume>
            <issue>20</issue>
            <fpage>2375</fpage>
            <page-range>2375-90</page-range>
            <pub-id pub-id-type="pmid">26980727</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Landgren</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kristinsson</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Goldin</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Caporaso</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Blimark</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mellqvist</surname>
                <given-names>UH</given-names>
              </name>
              <name>
                <surname>Wahlin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bjorkholm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turesson</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Jul</month>
            <day>23</day>
            <volume>114</volume>
            <issue>4</issue>
            <fpage>791</fpage>
            <page-range>791-5</page-range>
            <pub-id pub-id-type="pmid">19182202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vachon</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Therneau</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Foreman</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Colby</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Phelps</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Katzmann</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Jul</month>
            <day>23</day>
            <volume>114</volume>
            <issue>4</issue>
            <fpage>785</fpage>
            <page-range>785-90</page-range>
            <pub-id pub-id-type="pmid">19179466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhodapkar</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Waheed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Usmani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Papanikolaou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Petty</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shaughnessy</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hoering</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Orlowski</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Barlogie</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).</article-title>
            <source>Blood</source>
            <year>2014</year>
            <month>Jan</month>
            <day>02</day>
            <volume>123</volume>
            <issue>1</issue>
            <fpage>78</fpage>
            <page-range>78-85</page-range>
            <pub-id pub-id-type="pmid">24144643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Therneau</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cerhan</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Jan</month>
            <day>18</day>
            <volume>378</volume>
            <issue>3</issue>
            <fpage>241</fpage>
            <page-range>241-249</page-range>
            <pub-id pub-id-type="pmid">29342381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hillengass</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Usmani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Durie</surname>
                <given-names>BGM</given-names>
              </name>
              <name>
                <surname>Mateos</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Lonial</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Joao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Sanz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Riva</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>van de Donk</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Berdeja</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Terpos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zamagni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>San Miguel</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goldschmidt</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Giralt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Raje</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ludwig</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ocio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schots</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Einsele</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schjesvold</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Abildgaard</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lipe</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Dytfeld</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wirk</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Drake</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cavo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lahuerta</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lentzsch</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.</article-title>
            <source>Lancet Oncol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>e302</fpage>
            <page-range>e302-e312</page-range>
            <pub-id pub-id-type="pmid">31162104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leung</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bridoux</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hutchison</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Nasr</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Cockwell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fermand</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <collab>International Kidney and Monoclonal Gammopathy Research Group</collab>
            </person-group>
            <article-title>Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant.</article-title>
            <source>Blood</source>
            <year>2012</year>
            <month>Nov</month>
            <day>22</day>
            <volume>120</volume>
            <issue>22</issue>
            <fpage>4292</fpage>
            <page-range>4292-5</page-range>
            <pub-id pub-id-type="pmid">23047823</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baldini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guffanti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cesana</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Colombi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chiorboli</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Damilano</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Maiolo</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy.</article-title>
            <source>Blood</source>
            <year>1996</year>
            <month>Feb</month>
            <day>01</day>
            <volume>87</volume>
            <issue>3</issue>
            <fpage>912</fpage>
            <page-range>912-8</page-range>
            <pub-id pub-id-type="pmid">8562962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosi&#x000f1;ol</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cibeira</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Montoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rozman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esteve</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Filella</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Blad&#x000e9;</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>82</volume>
            <issue>4</issue>
            <fpage>428</fpage>
            <page-range>428-34</page-range>
            <pub-id pub-id-type="pmid">17418070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cesana</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Klersy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barbarano</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nosari</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Crugnola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pungolino</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gargantini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Granata</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Valentini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morra</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.</article-title>
            <source>J Clin Oncol</source>
            <year>2002</year>
            <month>Mar</month>
            <day>15</day>
            <volume>20</volume>
            <issue>6</issue>
            <fpage>1625</fpage>
            <page-range>1625-34</page-range>
            <pub-id pub-id-type="pmid">11896113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zeig-Owens</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Luft</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ramanathan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thoren</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Doddi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>UA</given-names>
              </name>
              <name>
                <surname>Mueller</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Giricz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prezant</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Landgren</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Myeloma precursor disease (MGUS) among rescue and recovery workers exposed to the World Trade Center disaster.</article-title>
            <source>Blood Cancer J</source>
            <year>2022</year>
            <month>Aug</month>
            <day>22</day>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>120</fpage>
            <pub-id pub-id-type="pmid">35995768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kleinstern</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Allmer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Muntifering</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sinnwell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Visram</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rajkumar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Dispenzieri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kyle</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Slager</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vachon</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.</article-title>
            <source>Blood Cancer J</source>
            <year>2022</year>
            <month>Apr</month>
            <day>19</day>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>67</fpage>
            <pub-id pub-id-type="pmid">35440099</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tahiru</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Izarra Santamaria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hultdin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Sp&#x000e4;th</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Progression patterns in monoclonal gammopathy of undetermined significance and multiple myeloma outcome: a cohort study in 42 patients.</article-title>
            <source>Exp Hematol Oncol</source>
            <year>2022</year>
            <month>Feb</month>
            <day>23</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <pub-id pub-id-type="pmid">35197127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCall</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Aaron</surname>
                <given-names>RK</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal Gammopathies in a Fracture Liaison Service.</article-title>
            <source>R I Med J (2013)</source>
            <year>2022</year>
            <month>Oct</month>
            <day>03</day>
            <volume>105</volume>
            <issue>8</issue>
            <fpage>28</fpage>
            <page-range>28-32</page-range>
            <pub-id pub-id-type="pmid">36173906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25248.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mouhieddine</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Weeks</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Ghobrial</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Monoclonal gammopathy of undetermined significance.</article-title>
            <source>Blood</source>
            <year>2019</year>
            <month>Jun</month>
            <day>06</day>
            <volume>133</volume>
            <issue>23</issue>
            <fpage>2484</fpage>
            <page-range>2484-2494</page-range>
            <pub-id pub-id-type="pmid">31010848</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
